Key clinical point: The addition of dendritic cell vaccine immunotherapy for prostate cancer (DCVAC/PCa) to chemotherapy followed by DCVAC/PCa maintenance therapy does not extend overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC).
Major finding: The overall survival was not significantly different between the DCVAC/PCa and placebo groups (median 23.9 months vs. 24.3 months; hazard ratio 1.04; P = .60). The treatment-emergent adverse event rate was 9.2% in the DCVAC/PCa group and 12.7% in the placebo group.
Study details: A double-blind, parallel-group, placebo-controlled, phase 3 randomized VIABLE study of 1,182 patients with mCRPC who were randomly assigned to receive DCVAC/PCa plus chemotherapy followed by DCVAC/PCa (n = 787) or placebo (n = 395).
Disclosures: This study was sponsored by Sotio a.s. The authors received research funding, grants, personal/advisory/consulting fees, and nonfinancial support or had stock ownership or patents.
Source: Vogelzang NJ et al. JAMA Oncol. 2022 (Feb 10). Doi: 10.1001/jamaoncol.2021.7298.